The estimated Net Worth of Kenneth Bate is at least $3.56 Milione dollars as of 1 April 2024. Mr. Bate owns over 32,489 units of Madrigal Pharmaceuticals Inc stock worth over $2,891,530 and over the last 14 years he sold MDGL stock worth over $0. In addition, he makes $670,000 as Independent Director at Madrigal Pharmaceuticals Inc.
Kenneth has made over 1 trades of the Madrigal Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 32,489 units of MDGL stock worth $2,411,334 on 1 April 2024.
The largest trade he's ever made was exercising 32,489 units of Madrigal Pharmaceuticals Inc stock on 1 April 2024 worth over $2,411,334. On average, Kenneth trades about 533 units every 0 days since 2010. As of 1 April 2024 he still owns at least 12,410 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Mr. Bate stock trades at the bottom of the page.
Kenneth M. Bate serves as Independent Director of the Company. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately-held biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009, he served in various positions at NitroMed, Inc., a publicly-held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, Mr. Bate was employed with Biogen, Inc., a publicly-held biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as chairman of the board of directors of the following publicly-held biopharmaceutical companies: AVEO Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Catabasis Pharmaceuticals, Inc. In addition, Mr. Bate currently serves on the board of directors of Epizyme, Inc., a publicly-held biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of directors of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceuticals, Inc. and Vanda Pharmaceuticals Inc., each a publicly-held biopharmaceutical company. Mr. Bate holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.
As the Independent Director of Madrigal Pharmaceuticals Inc, the total compensation of Kenneth Bate at Madrigal Pharmaceuticals Inc is $670,000. There are 10 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.
Kenneth Bate is 69, he's been the Independent Director of Madrigal Pharmaceuticals Inc since 2016. There are 4 older and 12 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
Kenneth's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman e Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include: